ONRIDE

Indication:

·        Prevention of nausea and vomiting associated with highly emetogenic cancer
chemotherapy

·        Prevention of nausea and vomiting associated with radiotherapy

·        Prevention of post-operative nausea and vomiting

·        Nausea-vomiting associated with pregnancy

·        Nausea-vomiting associated with gastroenteritis

Dosage & Administration:

Prevention of chemotherapy induced nausea & vomiting (CINV):

Adult-Tablet and oral solution: The recommended adult oral dosage of Onride (Ondansetron) is 24 mg given as three 8 mg tablets in highly emetogenic chemotherapy. In case of moderately emetogenic chemotherapy the oral dose is one 8 mg Onride (Ondansetron) tablet or 10 ml of Onride (Ondansetron) oral solution given twice daily.

Pediatric Patients-Tablet and oral solution: for pediatric patients 4 through 11 years of age the dosage is one 4 mg Onride tablet or 5ml of Onride solution should be administered 3 times a day for 1 to 2 days after completion of chemotherapy.

Radiotherapy induced nausea and vomiting:
Adult-Tablet and oral solution: the recommended oral dosage is one 8mg Onride tablet or 10ml of Onride oral solution given 3 times daily.

Post-operative nausea & vomiting (PONV):

Adult-Tablet and oral solution: the recommended dosage is 16 mg given as two 8 mg Onride tablets or 20 ml of Onride oral solution 1hour before induction of anesthesia.

Dosage adjustment for patients with impaired hepatic function-
Tablet and oral solution: The total daily dose of 8 mg should not be exceeded.

Preparation:

Onride tablet: Each film coated tablet contains Ondansetron Hydrochloride Dihydrate USP equivalent to
Ondansetron 8 mg.
Onride oral solution: Each 5 ml oral solution contains Ondansetron Hydrochloride Dihydrate USP equivalent to Ondansetron 4 mg.